An older patient and physician discuss medical information together. An older patient and physician discuss medical information together.

Veracyte's approach to bladder cancer testing

Understanding treatment decision-making for patients with bladder cancer

Bladder cancer is one of the most common cancers worldwide. In 2023, 82,290 people in the US are expected to be diagnosed with bladder cancer, and 16,710 patients are expected to die from the disease.1 The prognosis for bladder cancer can depend on several factors, including the cancer stage and type, whether the cancer is high- or low-grade, the patient’s general health, and more.2

These factors can also influence which treatment option may be best for a patient. Treatment may include immunotherapy, surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of therapeutic approaches.3 While deciding between treatment options can be complex, advances in genomic technology and testing can help physicians better determine the best path forward for their patients.


people in the US are estimated to be diagnosed with bladder cancer in 2023.1


deaths from bladder cancer are estimated to occur in the US in 2023.1


Learn about our exceptional prognostic testing for bladder cancer.

Identifying unmet needs through listening and collaboration

Veracyte collaborates closely with leading researchers and treating physicians in bladder cancer to gain insights into the molecular underpinnings of the disease to help address unmet clinical needs. Through this engagement, we learned that different bladder cancers behave differently based on their molecular subtype. By leveraging advanced genomic technologies, we determined that we could classify bladder cancer tumors into molecular subtypes to help clinicians better develop tailored treatment plans for their patients.

For clinicians, molecular classification of bladder cancer is needed for selecting appropriate treatments and doing everything in our power to improve outcomes and reduce the burden on our patients in their battle against bladder cancer.”

Associate Professor, Department of Urology, UCSF Medical Center

A physician showing information to an older patient on a tablet.


Better treatment planning with Decipher® Bladder Genomic Classifier

The Decipher Bladder Genomic Classifier helps physicians and their patients with bladder cancer navigate complex treatment decisions. The Decipher Bladder test uses whole-transcriptome analysis and machine-learning technology to classify bladder tumors into five molecular subtypes, each with distinct biological characteristics. Armed with this information, physicians may better guide bladder cancer treatment decisions for their patients.

An older man holding a smiling baby.

Learn about Decipher for bladder cancer


  1. Bladder Cancer: Statistics. Cancer.Net. Published March 2023. Accessed August 28, 2023.

  2. Bladder Cancer Prognosis and Survival Rates. National Cancer Institute. Published April 27, 2023. Accessed August 28, 2023.

  3. Bladder Cancer. Mayo Clinic. Published April 19, 2022. Accessed August 28, 2023.

The Decipher Bladder Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.

This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.